Coupled with the slightly disproportionate reporting of diabetic ketoacidosis associated with GLP-1 RAs when they occur without combination with insulin (Yang et al., 2022), there is a need to be concerned about ketoacidosis as a potential adverse effect when using GLP-1 RAs. The gene discussed is INS; the disease is diabetic ketoacidosis.